AAV-encoded CaV2.2 peptide aptamer CBD3A6K for primary sensory neuron-targeted treatment of established neuropathic pain

Abstract

Transmission of pain signals from primary sensory neurons to secondary neurons of the central nervous system is critically dependent on presynaptic voltage-gated calcium channels. Calcium channel-binding domain 3 (CBD3), derived from the collapsin response mediator protein 2 (CRMP2), is a peptide aptamer that is effective in blocking N-type voltage-gated calcium channel (CaV2.2) activity. We previously reported that recombinant adeno-associated virus (AAV)-mediated restricted expression of CBD3 affixed to enhanced green fluorescent protein (EGFP) in primary sensory neurons prevents the development of cutaneous mechanical hypersensitivity in a rat neuropathic pain model. In this study, we tested whether this strategy is effective in treating established pain. We constructed AAV6-EGFP-CBD3A6K (AAV6-CBD3A6K) expressing a fluorescent CBD3A6K (replacing A to K at position 6 of CBD3 peptide), which is an optimized variant of the parental CBD3 peptide that is a more potent blocker of CaV2.2. Delivery of AAV6-CBD3A6K into lumbar (L) 4 and 5 dorsal root ganglia (DRG) of rats 2 weeks following tibial nerve injury (TNI) induced transgene expression in neurons of these DRG and their axonal projections, accompanied by attenuation of pain behavior. We additionally observed that the increased CaV2.2α1b immunoreactivity in the ipsilateral spinal cord dorsal horn and DRG following TNI was significantly normalized by AAV6-CBD3A6K treatment. Finally, the increased neuronal activity in the ipsilateral dorsal horn that developed after TNI was reduced by AAV6-CBD3A6K treatment. Collectively, these results indicate that DRG-restricted AAV6 delivery of CBD3A6K is an effective analgesic molecular strategy for the treatment of established neuropathic pain.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

References

  1. 1.

    Dzau VJ, Pizzo PA. Relieving pain in America: insights from an Institute of Medicine committee. JAMA. 2014;312:1507–8. https://doi.org/10.1001/jama.2014.12986

  2. 2.

    Loeser JD. Relieving pain in America. Clin J Pain. 2012;28:185–6. https://doi.org/10.1097/AJP.0b013e318230f6c1

  3. 3.

    Basbaum AI, Bautista DM, Scherrer G, Julius D. Cellular and molecular mechanisms of pain. Cell. 2009;139:267–84. https://doi.org/10.1016/j.cell.2009.09.028

  4. 4.

    Costigan M, Scholz J, Woolf CJ. Neuropathic pain: a maladaptive response of the nervous system to damage. Annu Rev Neurosci. 2009;32:1–32. https://doi.org/10.1146/annurev.neuro.051508.135531

  5. 5.

    Campbell JN, Meyer RA. Mechanisms of neuropathic pain. Neuron. 2006;52:77–92. https://doi.org/10.1016/j.neuron.2006.09.021

  6. 6.

    Bucci G, Mochida S, Stephens GJ. Inhibition of synaptic transmission and G protein modulation by synthetic CaV2.2 Ca(2)+ channel peptides. J Physiol. 2011;589:3085–101. https://doi.org/10.1113/jphysiol.2010.204735

  7. 7.

    Bell TJ, Thaler C, Castiglioni AJ, Helton TD, Lipscombe D. Cell-specific alternative splicing increases calcium channel current density in the pain pathway. Neuron. 2004;41:127–38.

  8. 8.

    Altier C, Dale CS, Kisilevsky AE, Chapman K, Castiglioni AJ, Matthews EA, et al. Differential role of N-type calcium channel splice isoforms in pain. J Neurosci. 2007;27:6363–73. https://doi.org/10.1523/JNEUROSCI.0307-07.2007

  9. 9.

    Bauer CS, Nieto-Rostro M, Rahman W, Tran-Van-Minh A, Ferron L, Douglas L, et al. The increased trafficking of the calcium channel subunit alpha2delta-1 to presynaptic terminals in neuropathic pain is inhibited by the alpha2delta ligand pregabalin. J Neurosci. 2009;29:4076–88. https://doi.org/10.1523/JNEUROSCI.0356-09.2009

  10. 10.

    Ji RR, Strichartz G. Cell signaling and the genesis of neuropathic pain. Sci STKE. 2004;2004:reE14 https://doi.org/10.1126/stke.2522004re14

  11. 11.

    Tyagarajan S, Chakravarty PK, Park M, Zhou B, Herrington JB, Ratliff K, et al. A potent and selective indole N-type calcium channel (Ca(v)2.2) blocker for the treatment of pain. Bioorg Med Chem Lett. 2011;21:869–73. https://doi.org/10.1016/j.bmcl.2010.11.067

  12. 12.

    Liang M, Yin XL, Shi HB, Li CY, Li XY, Song NY, et al. Bilirubin augments Ca(2+) load of developing bushy neurons by targeting specific subtype of voltage-gated calcium channels. Sci Rep. 2017;7:431 https://doi.org/10.1038/s41598-017-00275-9

  13. 13.

    Norton RS, McDonough SI. Peptides targeting voltage-gated calcium channels. Curr Pharm Des. 2008;14:2480–91.

  14. 14.

    Perret D, Luo ZD. Targeting voltage-gated calcium channels for neuropathic pain management. Neurotherapeutics. 2009;6:679–92. https://doi.org/10.1016/j.nurt.2009.07.006

  15. 15.

    Pexton T, Moeller-Bertram T, Schilling JM, Wallace MS. Targeting voltage-gated calcium channels for the treatment of neuropathic pain: a review of drug development. Expert Opin Investig Drugs. 2011;20:1277–84. https://doi.org/10.1517/13543784.2011.600686

  16. 16.

    Vink S, Alewood PF. Targeting voltage-gated calcium channels: developments in peptide and small-molecule inhibitors for the treatment of neuropathic pain. Br J Pharmacol. 2012;167:970–89. https://doi.org/10.1111/j.1476-5381.2012.02082.x

  17. 17.

    Zamponi GW. Targeting voltage-gated calcium channels in neurological and psychiatric diseases. Nat Rev Drug Discov. 2016;15:19–34. https://doi.org/10.1038/nrd.2015.5

  18. 18.

    Park J, Luo ZD. Calcium channel functions in pain processing. Channels. 2010;4:510–7.

  19. 19.

    Patel R, Montagut-Bordas C, Dickenson AH. Calcium channel modulation as a target in chronic pain control. Br J Pharmacol. 2018;175:2173–84. https://doi.org/10.1111/bph.13789

  20. 20.

    McGivern JG. Targeting N-type and T-type calcium channels for the treatment of pain. Drug Discov Today. 2006;11:245–53. https://doi.org/10.1016/S1359-6446(05)03662-7

  21. 21.

    Brittain JM, Duarte DB, Wilson SM, Zhu W, Ballard C, Johnson PL, et al. Suppression of inflammatory and neuropathic pain by uncoupling CRMP-2 from the presynaptic Ca(2)(+) channel complex. Nat Med. 2011;17:822–9. https://doi.org/10.1038/nm.2345

  22. 22.

    Moutal A, Wang Y, Yang X, Ji Y, Luo S, Dorame A, et al. Dissecting the role of the CRMP2-neurofibromin complex on pain behaviors. Pain. 2017;158:2203–21. https://doi.org/10.1097/j.pain.0000000000001026

  23. 23.

    Hoppe-Seyler F, Crnkovic-Mertens I, Tomai E, Butz K. Peptide aptamers: specific inhibitors of protein function. Curr Mol Med. 2004;4:529–38.

  24. 24.

    Brittain JM, Piekarz AD, Wang Y, Kondo T, Cummins TR, Khanna R. An atypical role for collapsin response mediator protein 2 (CRMP-2) in neurotransmitter release via interaction with presynaptic voltage-gated calcium channels. J Biol Chem. 2009;284:31375–90. https://doi.org/10.1074/jbc.M109.009951

  25. 25.

    Francois-Moutal L, Wang Y, Moutal A, Cottier KE, Melemedjian OK, Yang X, et al. A membrane-delimited N-myristoylated CRMP2 peptide aptamer inhibits CaV2.2 trafficking and reverses inflammatory and postoperative pain behaviors. Pain. 2015;156:1247–64. https://doi.org/10.1097/j.pain.0000000000000147

  26. 26.

    Xie JY, Chew LA, Yang X, Wang Y, Qu C, Wang Y, et al. Sustained relief of ongoing experimental neuropathic pain by a CRMP2 peptide aptamer with low abuse potential. Pain. 2016;157:2124–40. https://doi.org/10.1097/j.pain.0000000000000628

  27. 27.

    Simms BA, Zamponi GW. Neuronal voltage-gated calcium channels: structure, function, and dysfunction. Neuron. 2014;82:24–45. https://doi.org/10.1016/j.neuron.2014.03.016

  28. 28.

    Chi XX, Schmutzler BS, Brittain JM, Wang Y, Hingtgen CM, Nicol GD, et al. Regulation of N-type voltage-gated calcium channels (Cav2.2) and transmitter release by collapsin response mediator protein-2 (CRMP-2) in sensory neurons. J Cell Sci. 2009;122:4351–62. https://doi.org/10.1242/jcs.053280

  29. 29.

    Fischer G, Pan B, Vilceanu D, Hogan QH, Yu H. Sustained relief of neuropathic pain by AAV-targeted expression of CBD3 peptide in rat dorsal root ganglion. Gene Ther. 2014;21:44–51. https://doi.org/10.1038/gt.2013.56

  30. 30.

    Piekarz AD, Due MR, Khanna M, Wang B, Ripsch MS, Wang R, et al. CRMP-2 peptide mediated decrease of high and low voltage-activated calcium channels, attenuation of nociceptor excitability, and anti-nociception in a model of AIDS therapy-induced painful peripheral neuropathy. Mol Pain. 2012;8:54 https://doi.org/10.1186/1744-8069-8-54

  31. 31.

    Yu H, Fischer G, Ferhatovic L, Fan F, Light AR, Weihrauch D, et al. Intraganglionic AAV6 results in efficient and long-term gene transfer to peripheral sensory nervous system in adult rats. PLoS ONE. 2013;8:e61266 https://doi.org/10.1371/journal.pone.0061266

  32. 32.

    Hughes DI, Scott DT, Todd AJ, Riddell JS. Lack of evidence for sprouting of Abeta afferents into the superficial laminas of the spinal cord dorsal horn after nerve section. J Neurosci. 2003;23:9491–9.

  33. 33.

    Yu H, Pan B, Weyer A, Wu HE, Meng J, Fischer G, et al. CaMKII controls whether touch is painful. J Neurosci. 2015;35:14086–102. https://doi.org/10.1523/JNEUROSCI.1969-15.2015

  34. 34.

    D’Arco M, Margas W, Cassidy JS, Dolphin AC. The upregulation of alpha2delta-1 subunit modulates activity-dependent Ca2+signals in sensory neurons. J Neurosci. 2015;35:5891–903. https://doi.org/10.1523/JNEUROSCI.3997-14.2015

  35. 35.

    Lu SG, Zhang XL, Luo ZD, Gold MS. Persistent inflammation alters the density and distribution of voltage-activated calcium channels in subpopulations of rat cutaneous DRG neurons. Pain. 2010;151:633–43. https://doi.org/10.1016/j.pain.2010.08.030

  36. 36.

    Hoppa MB, Lana B, Margas W, Dolphin AC, Ryan T. A. alpha2delta expression sets presynaptic calcium channel abundance and release probability. Nature. 2012;486:122–5. https://doi.org/10.1038/nature11033

  37. 37.

    Westenbroek RE, Hell JW, Warner C, Dubel SJ, Snutch TP, Catterall WA. Biochemical properties and subcellular distribution of an N-type calcium channel alpha 1 subunit. Neuron. 1992;9:1099–115.

  38. 38.

    Cizkova D, Marsala J, Lukacova N, Marsala M, Jergova S, Orendacova J, et al. Localization of N-type Ca2+ channels in the rat spinal cord following chronic constrictive nerve injury. Exp Brain Res. 2002;147:456–63. https://doi.org/10.1007/s00221-002-1217-3

  39. 39.

    Todd AJ. Neuronal circuitry for pain processing in the dorsal horn. Nat Rev Neurosci. 2010;11:823–36. https://doi.org/10.1038/nrn2947

  40. 40.

    Wilson SM, Brittain JM, Piekarz AD, Ballard CJ, Ripsch MS, Cummins TR, et al. Further insights into the antinociceptive potential of a peptide disrupting the N-type calcium channel-CRMP-2 signaling complex. Channels. 2011;5:449–56. https://doi.org/10.4161/chan.5.5.17363

  41. 41.

    Xiang H, Liu Z, Wang F, Xu H, Roberts C, Fischer G, et al. Primary sensory neuron-specific interference of TRPV1 signaling by AAV-encoded TRPV1 peptide aptamer attenuates neuropathic pain. Mol Pain. 2017;13:1744806917717040 https://doi.org/10.1177/1744806917717040

  42. 42.

    Swett JE, Torigoe Y, Elie VR, Bourassa CM, Miller PG. Sensory neurons of the rat sciatic nerve. Exp Neurol. 1991;114:82–103.

  43. 43.

    Heinke B, Balzer E, Sandkuhler J. Pre- and postsynaptic contributions of voltage-dependent Ca2+channels to nociceptive transmission in rat spinal lamina I neurons. Eur J Neurosci. 2004;19:103–11.

  44. 44.

    Rycroft BK, Vikman KS, Christie MJ. Inflammation reduces the contribution of N-type calcium channels to primary afferent synaptic transmission onto NK1 receptor-positive lamina I neurons in the rat dorsal horn. J Physiol. 2007;580:883–94. https://doi.org/10.1113/jphysiol.2006.125880

  45. 45.

    Chai Z, Wang C, Huang R, Wang Y, Zhang X, Wu Q, et al. CaV2.2 gates calcium-independent but voltage-dependent secretion in mammalian sensory neurons. Neuron. 2017;96:1317–26. https://doi.org/10.1016/j.neuron.2017.10.028. e1314

  46. 46.

    Zhang FX, Gadotti VM, Souza IA, Chen L, Zamponi GW. BK potassium channels suppress cavalpha2delta subunit function to reduce inflammatory and neuropathic pain. Cell Rep. 2018;22:1956–64. https://doi.org/10.1016/j.celrep.2018.01.073

  47. 47.

    Bezprozvanny I, Zhong P, Scheller RH, Tsien RW. Molecular determinants of the functional interaction between syntaxin and N-type Ca2+ channel gating. Proc Natl Acad Sci USA. 2000;97:13943–8. https://doi.org/10.1073/pnas.220389697

  48. 48.

    Cassidy JS, Ferron L, Kadurin I, Pratt WS, Dolphin AC. Functional exofacially tagged N-type calcium channels elucidate the interaction with auxiliary alpha2delta-1 subunits. Proc Natl Acad Sci USA. 2014;111:8979–84. https://doi.org/10.1073/pnas.1403731111

  49. 49.

    Diverse-Pierluissi M, Dunlap K. Interaction of convergent pathways that inhibit N-type calcium currents in sensory neurons. Neuroscience. 1995;65:477–83.

  50. 50.

    Kadurin I, Rothwell SW, Lana B, Nieto-Rostro M, Dolphin AC. LRP1 influences trafficking of N-type calcium channels via interaction with the auxiliary alpha2delta-1 subunit. Sci Rep. 2017;7:43802 https://doi.org/10.1038/srep43802

  51. 51.

    Leroy J, Richards MW, Butcher AJ, Nieto-Rostro M, Pratt WS, Davies A, et al. Interaction via a key tryptophan in the I-II linker of N-type calcium channels is required for beta1 but not for palmitoylated beta2, implicating an additional binding site in the regulation of channel voltage-dependent properties. J Neurosci. 2005;25:6984–96. https://doi.org/10.1523/JNEUROSCI.1137-05.2005

  52. 52.

    Omote K, Kawamata M, Satoh O, Iwasaki H, Namiki A. Spinal antinociceptive action of an N-Type voltage-dependent calcium channel blocker and the synergistic interaction with morphine. Anesthesiology. 1996;84:636–43.

  53. 53.

    Sheng ZH, Rettig J, Cook T, Catterall WA. Calcium-dependent interaction of N-type calcium channels with the synaptic core complex. Nature. 1996;379:451–4. https://doi.org/10.1038/379451a0

  54. 54.

    Ju W, Li Q, Allette YM, Ripsch MS, White FA & Khanna R. Suppression of pain-related behavior in two distinct rodent models of peripheral neuropathy by a homopolyarginine-conjugated CRMP2 peptide. J Neurochem. https://doi.org/10.1111/jnc.12070 (2012).

  55. 55.

    Ripsch MS, Ballard CJ, Khanna M, Hurley JH, White FA, Khanna R. A Peptide uncoupling crmp-2 from the presynaptic ca(2+) channel complex demonstrates efficacy in animal models of migraine and aids therapy-induced neuropathy. Transl Neurosci. 2012;3:1–8. https://doi.org/10.2478/s13380-012-0002-4

  56. 56.

    Ip JP, Fu AK, Ip NY. CRMP2: functional roles in neural development and therapeutic potential in neurological diseases. Neuroscientist. 2014;20:589–98. https://doi.org/10.1177/1073858413514278

  57. 57.

    Suzuki Y, Nakagomi S, Namikawa K, Kiryu-Seo S, Inagaki N, Kaibuchi K, et al. Collapsin response mediator protein-2 accelerates axon regeneration of nerve-injured motor neurons of rat. J Neurochem. 2003;86:1042–50.

  58. 58.

    Kamiya Y, Saeki K, Takiguchi M. CDK5, CRMP2 and NR2B in spinal dorsal horn and dorsal root ganglion have different role in pain signaling between neuropathic pain model and inflammatory pain model. Eur J Anaesthesiol. 2013;30:214.

  59. 59.

    Zhang JN, Koch JC. Collapsin response mediator protein-2 plays a major protective role in acute axonal degeneration. Neural Regen Res. 2017;12:692–5. https://doi.org/10.4103/1673-5374.206631

  60. 60.

    Moutal A, Luo S, Largent-Milnes, TM, Vanderah TW, Khanna R. Cdk5-mediated CRMP2 phosphorylation is necessary and sufficient for peripheral neuropathic pain. Neurobiol Pain. In press, https://doi.org/10.1016/j.ynpai.2018.1007.1003 (2018).

  61. 61.

    Chapman V, Suzuki R, Dickenson AH. Electrophysiological characterization of spinal neuronal response properties in anaesthetized rats after ligation of spinal nerves L5-L6. J Physiol. 1998;507:881–94.

  62. 62.

    Takaishi K, Eisele JH Jr., Carstens E. Behavioral and electrophysiological assessment of hyperalgesia and changes in dorsal horn responses following partial sciatic nerve ligation in rats. Pain. 1996;66:297–306.

  63. 63.

    Palecek J, Paleckova V, Dougherty PM, Carlton SM, Willis WD. Responses of spinothalamic tract cells to mechanical and thermal stimulation of skin in rats with experimental peripheral neuropathy. J Neurophysiol. 1992;67:1562–73. https://doi.org/10.1152/jn.1992.67.6.1562

  64. 64.

    Laird JM, Bennett GJ. An electrophysiological study of dorsal horn neurons in the spinal cord of rats with an experimental peripheral neuropathy. J Neurophysiol. 1993;69:2072–85. https://doi.org/10.1152/jn.1993.69.6.2072

  65. 65.

    Brustovetsky T, Pellman JJ, Yang XF, Khanna R, Brustovetsky N. Collapsin response mediator protein 2 (CRMP2) interacts with N-methyl-D-aspartate (NMDA) receptor and Na+/Ca2+exchanger and regulates their functional activity. J Biol Chem. 2014;289:7470–82. https://doi.org/10.1074/jbc.M113.518472

  66. 66.

    Dustrude ET, Wilson SM, Ju W, Xiao Y, Khanna R. CRMP2 protein SUMOylation modulates NaV1.7 channel trafficking. J Biol Chem. 2013;288:24316–31. https://doi.org/10.1074/jbc.M113.474924

  67. 67.

    Brittain JM, Pan R, You H, Brustovetsky T, Brustovetsky N, Zamponi GW, et al. Disruption of NMDAR-CRMP-2 signaling protects against focal cerebral ischemic damage in the rat middle cerebral artery occlusion model. Channels (Austin) 2012;6:52–59.

  68. 68.

    Kanellopoulos AH, Koenig J, Huang H, Pyrski M, Millet Q, Lolignier S, et al. Mapping protein interactions of sodium channel NaV1.7 using epitope-tagged gene-targeted mice. Embo J. 2018;37:427–45. https://doi.org/10.15252/embj.201796692

  69. 69.

    Sumi T, Imasaki T, Aoki M, Sakai N, Nitta E, Shirouzu M, et al. Structural insights into the altering function of CRMP2 by phosphorylation. Cell Struct Funct. 2018;43:15–23. https://doi.org/10.1247/csf.17025

  70. 70.

    Wilson SM, Ki Yeon S, Yang XF, Park KD, Khanna R. Differential regulation of collapsin response mediator protein 2 (CRMP2) phosphorylation by GSK3ss and CDK5 following traumatic brain injury. Front Cell Neurosci. 2014;8:135 https://doi.org/10.3389/fncel.2014.00135

  71. 71.

    Brittain JM, Wang Y, Eruvwetere O, Khanna R. Cdk5-mediated phosphorylation of CRMP-2 enhances its interaction with CaV2.2. FEBS Lett. 2012;586:3813–8. https://doi.org/10.1016/j.febslet.2012.09.022

  72. 72.

    Bolash RB, Niazi T, Kumari M, Azer G, Mekhail N. Efficacy of a targeted drug delivery on-demand bolus option for chronic pain. Pain Pract. 2018;18:305–13. https://doi.org/10.1111/papr.12602

  73. 73.

    Hayek SM, Sweet JA, Miller JP, Sayegh RR. Successful management of corneal neuropathic pain with intrathecal targeted drug delivery. Pain Med. 2016;17:1302–7. https://doi.org/10.1093/pm/pnv058

  74. 74.

    Berta T, Qadri Y, Tan PH, Ji RR. Targeting dorsal root ganglia and primary sensory neurons for the treatment of chronic pain. Expert Opin Ther Targets. 2017;21:695–703. https://doi.org/10.1080/14728222.2017.1328057

  75. 75.

    Guha D, Shamji MF. The dorsal root Ganglion in the pathogenesis of chronic neuropathic pain. Neurosurgery. 2016;63:118–26. https://doi.org/10.1227/NEU.0000000000001255

  76. 76.

    Hogan QH. Labat lecture: the primary sensory neuron: where it is, what it does, and why it matters. Reg Anesth Pain Med. 2010;35:306–11. https://doi.org/10.1097/AAP.0b013e3181d2375e

  77. 77.

    Terashima T, Ogawa N, Nakae Y, Sato T, Katagi M, Okano J, et al. Gene therapy for neuropathic pain through siRNA-IRF5 gene delivery with homing peptides to microglia. Mol Ther Nucleic Acids. 2018;11:203–15. https://doi.org/10.1016/j.omtn.2018.02.007

  78. 78.

    Zheng Y, Sethi R, Mangala LS, Taylor C, Goldsmith J, Wang M, et al. Tuning microtubule dynamics to enhance cancer therapy by modulating FER-mediated CRMP2 phosphorylation. Nat Commun. 2018;9:476 https://doi.org/10.1038/s41467-017-02811-7

  79. 79.

    Fischer G, Kostic S, Nakai H, Park F, Sapunar D, Yu H, et al. Direct injection into the dorsal root ganglion: technical, behavioral, and histological observations. J Neurosci Methods. 2011;199:43–55.

  80. 80.

    Chaplan SR, Bach FW, Pogrel JW, Chung JM, Yaksh TL. Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods. 1994;53:55–63.

  81. 81.

    Wu HE, Gemes G, Zoga V, Kawano T, Hogan QH. Learned avoidance from noxious mechanical simulation but not threshold semmes weinstein filament stimulation after nerve injury in rats. J Pain. 2010;11:280–6. https://doi.org/10.1016/j.jpain.2009.07.011

  82. 82.

    Yu H, Fischer G, Jia G, Reiser J, Park F, Hogan QH. Lentiviral gene transfer into the dorsal root ganglion of adult rats. Mol Pain. 2011;7:63.

  83. 83.

    Liu Z, Wang F, Fischer G, Hogan QH & Yu H. Peripheral nerve injury induces loss of nociceptive neuron-specific Galphai-interacting protein in neuropathic pain rat. Mol Pain. https://doi.org/10.1177/1744806916646380 (2016).

  84. 84.

    Ramer MS, Duraisingam I, Priestley JV, McMahon SB. Two-tiered inhibition of axon regeneration at the dorsal root entry zone. J Neurosci. 2001;21:2651–60.

  85. 85.

    Xiang H, Xu H, Fan F, Shin SM, Hogan QH & Yu H. Glial fibrillary acidic protein promoter determines transgene expression in satellite glial cells following intraganglionic adeno-associated virus delivery in adult rats. J Neurosci Res. https://doi.org/10.1002/jnr.24183 (2017).

Download references

Acknowledgements

This research was supported by a grant from the Department of Veterans Affairs Rehabilitation Research and Development I01RX001940 (to Q. Hogan). R. Khanna is supported by grants from National Institutes of Health Awards (1R01NS098772 and 1R01DA042852). H. Xiang was a recipient of National Natural Science Foundation of China (81802190, 81772412). Y. Cai was a recipient of Chinese Scholarship Council.

Author information

Correspondence to Hongwei Yu.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Yu, H., Shin, S., Xiang, H. et al. AAV-encoded CaV2.2 peptide aptamer CBD3A6K for primary sensory neuron-targeted treatment of established neuropathic pain. Gene Ther 26, 308–323 (2019). https://doi.org/10.1038/s41434-019-0082-7

Download citation

Further reading